Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Aronson

Showing results (331-340 of 634) with videos related to

Pageof 64
Sort By:
Journal of the Royal Society of Medicine|February 24, 2012
Jacob Lockhart Clarke's and John Hughlings Jackson's first description of syringomyeliaManoj Ramachandran, Jeffrey K Aronson
British Journal of Clinical Pharmacology|June 30, 2015
The law of mass action and the pharmacological concentration-effect curve: resolving the paradox of apparently non-dose-related adverse drug reactionsJeffrey K Aronson, Robin E Ferner
British Journal of Clinical Pharmacology|May 3, 2020
Me-too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines listsJeffrey K Aronson, A Richard Green
BMJ (Clinical Research Ed.)|December 5, 1992
ABC of monitoring drug therapy. Aminoglycoside antibioticsJ K Aronson, D J Reynolds
Brain : a Journal of Neurology|March 28, 2021
Was this Thomas Willis's greatest clinical success?Andrew N Williams, Jeffrey K Aronson
BMJ (Clinical Research Ed.)|April 3, 2015
A licence to cureJeffrey K Aronson, Robin E Ferner
BMJ Evidence-Based Medicine|February 1, 2019
Lorcaserin in obesity: minimal benefits and ill-defined harmsIgho J Onakpoya, Jeffrey K Aronson
Trials|May 1, 2025
Clinical Study Reports-a systematic review with thematic synthesis: Part 2. Studying benefits, harms, and the benefit to harm balance of pharmacological interventionsJ K Aronson, I J Onakpoya
British Journal of Clinical Pharmacology|August 6, 2017
Unlicensed and off-label uses of medicines: definitions and clarification of terminologyJeffrey K Aronson, Robin E Ferner
BMJ (Clinical Research Ed.)|May 19, 2016
How similar are biosimilars?Jeffrey K Aronson, Robin E Ferner
Pageof 64

Showing results (331-340 of 634) with videos related to

Sort By:
Pageof 64
Journal of the Royal Society of Medicine|February 24, 2012
Jacob Lockhart Clarke's and John Hughlings Jackson's first description of syringomyeliaManoj Ramachandran, Jeffrey K Aronson
British Journal of Clinical Pharmacology|June 30, 2015
The law of mass action and the pharmacological concentration-effect curve: resolving the paradox of apparently non-dose-related adverse drug reactionsJeffrey K Aronson, Robin E Ferner
British Journal of Clinical Pharmacology|May 3, 2020
Me-too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines listsJeffrey K Aronson, A Richard Green
BMJ (Clinical Research Ed.)|December 5, 1992
ABC of monitoring drug therapy. Aminoglycoside antibioticsJ K Aronson, D J Reynolds
Brain : a Journal of Neurology|March 28, 2021
Was this Thomas Willis's greatest clinical success?Andrew N Williams, Jeffrey K Aronson
BMJ (Clinical Research Ed.)|April 3, 2015
A licence to cureJeffrey K Aronson, Robin E Ferner
BMJ Evidence-Based Medicine|February 1, 2019
Lorcaserin in obesity: minimal benefits and ill-defined harmsIgho J Onakpoya, Jeffrey K Aronson
Trials|May 1, 2025
Clinical Study Reports-a systematic review with thematic synthesis: Part 2. Studying benefits, harms, and the benefit to harm balance of pharmacological interventionsJ K Aronson, I J Onakpoya
British Journal of Clinical Pharmacology|August 6, 2017
Unlicensed and off-label uses of medicines: definitions and clarification of terminologyJeffrey K Aronson, Robin E Ferner
BMJ (Clinical Research Ed.)|May 19, 2016
How similar are biosimilars?Jeffrey K Aronson, Robin E Ferner
Pageof 64